What are Some Glutaminase Inhibitors in Development?
One of the most well-known glutaminase inhibitors is CB-839, also known as Telaglenastat. This drug has shown efficacy in preclinical models and is being evaluated in clinical trials for various cancers, including renal cell carcinoma and triple-negative breast cancer. Other inhibitors like BPTES and compound 968 are also being studied for their potential therapeutic benefits.
